Back to Journals » Journal of Asthma and Allergy » Volume 13

Profile of Baricitinib and Its Potential in the Treatment of Moderate to Severe Atopic Dermatitis: A Short Review on the Emerging Clinical Evidence

Authors Napolitano M, Fabbrocini G, Cinelli E, Stingeni L, Patruno C

Received 12 November 2019

Accepted for publication 23 December 2019

Published 31 January 2020 Volume 2020:13 Pages 89—94

DOI https://doi.org/10.2147/JAA.S206387

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Luis Garcia-Marcos


Maddalena Napolitano,1 Gabriella Fabbrocini,2 Eleonora Cinelli,2 Luca Stingeni,3 Cataldo Patruno4

1Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy; 2Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy; 3Dermatology Section, Department of Medicine, University of Perugia, Perugia, Italy; 4Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy

Correspondence: Maddalena Napolitano
Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy
Tel +39 0817462439
Email maddy.napolitano@gmail.com

Abstract: Atopic dermatitis (AD) is the most common chronic cutaneous inflammatory disease of childhood, affecting up to 25% of children; its prevalence in adulthood is currently unknown, since studies reported that AD may affect 0.3– 14.3% of adult population. In the last decade, the advanced understanding of AD molecular pathways along with patient’s and physician’s demand for more effective therapies, led to the introduction of new therapeutic agents. Baricitinib is an oral JAK inhibitor highly selective for JAK1 and JAK2. Treatment with baricitinib improved the signs and symptoms of moderate-to-severe AD compared to placebo, but it will be essential to better understand the safety profile of this drug.

Keywords: baricitinib, adult atopic dermatitis, small molecules, JAK/STAT


Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]